Guidance

Subcategories:Clinical Criteria/Guidelines Ethics Legal Updates Legislation & Advocacy Meeting Reports Research Rheum

Figure 2: High-resolution computed tomography showed evidence of interstitial lung disease.

High-resolution computed tomography shows evidence of ILD.

The ACR/CHEST ILD Guidelines in Practice, a video
In collaboration with the American College of Chest Physicians, the ACR released two new comprehensive guidelines aimed at improving the screening, monitoring, and treatment of patients with interstitial lung disease (ILD) secondary to systemic autoimmune rheumatic diseases (SARDs). Recently, Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, director of the Toronto Scleroderma Program and principal investigator for the guideline, and Elana J. Bernstein, MD, MSc, Florence Irving associate professor of medicine in the Division of Rheumatology at Columbia University, New York City, and co-first author, presented a webinar to talk about how the guidelines were developed and present some of the recommendations and their rationale: Watch the recording now!

Experiencing EULAR: An ARHP Perspective

Pamela J. Degotardi, PhD | November 1, 2009

I’m writing this column in my hotel room in rainy, somewhat chilly, Copenhagen. So much for the summer dresses that I packed in preparation for attending this European League Against Rheumatism (EULAR) meeting. Instead it’s been all about layering and trying to stay dry, dodging puddles, and struggling with blown-out umbrellas. The rain has impeded any desire to explore Tivoli gardens, but it hasn’t dampened the friendliness and welcome of our European counterparts in EULAR’s Allied Health Professionals (AHP) standing committee.

Within Our Reach–Funded Research May Hold Key to Unlocking the CNS and Suppressing RA

Staff | November 1, 2009

Studies recently published in Arthritis & Rheumatism show that a key chemical produced by the central nervous system (CNS) decreases inflammation and suppresses production of proteins known to play a role in rheumatoid arthritis (RA). This opens the way for developing a novel class of drugs that mimic this effect of the CNS on RA.

Pharmaceutical Tourism

Bruce N. Cronstein, MD | November 1, 2009

Could trade agreements and not bulky legislation be the key to cheaper drugs?

The Canes of York

David S. Pisetsky, MD, PhD | November 1, 2009

What can a walking stick tell us about U.S. healthcare?

The Health Buzz

Stanley B. Cohen, MD | November 1, 2009

What is the ACR doing with healthcare reform?

Another Vocabulary for Rheumatology Research

Gretchen Henkel | October 1, 2009

Matt Liang, MD, MPH, addresses patients’ authentic concerns

Reading Rheum

Gail C. Davis, RN, EdD; Michael M. Ward, MD; | October 1, 2009

Handpicked Reviews of Contemporary Literature

Stimulus Package Creates Flurry of Research Funds

Kurt Ullman | October 1, 2009

Researchers celebrate boon, but wonder what will happen next

What Has RheumPAC Done for You Lately?

Staff | October 1, 2009

RheumPAC, the ACR’s political action committee, is dedicated to ensuring that rheumatology issues are addressed in healthcare reform. The best way to make sure the issues affecting rheumatology are being heard is to engage in the discussions and to contribute to congressional campaigns.

AMA House of Delegates Welcomes President Barack Obama

Staff | October 1, 2009

One cannot open a paper, turn on the television, listen to the radio, or surf the Internet without finding something about healthcare reform. This heated topic is at the center of the media and was the focus of the American Medical Association’s (AMA’s) 2009 House of Delegates meeting in June, where President Barack Obama addressed the delegates of the largest physician’s organization in the United States.